Long-Term Safety and Effectiveness of Rituximab Biosimilar RTXM83: A Retrospective Extension Study in Brazilian Patients with Diffuse Large B-Cell Lymphoma

Overview

Journal Oncol Ther

Specialty Oncology

Date 2024 Jun 3

PMID 38829416

Authors

Marcia Torresan Delamain

Ana Carolina Ferreira Cardoso

Fernando Vieira Pericole

Sergio Shusterschitz da Silva Araujo

Laura Fogliatto

Marcia Higashi

Juliana Pereira

Roberto Luiz da Silva

Gustavo Werutsky

Patricia de Paulo Giacon Radtke

Marco Aurelio Salvino

Vivienne Castilho

Affiliations

Soon will be listed here.

Abstract

Introduction: RTXM83, a biosimilar of rituximab, was approved after physicochemical, functional, non-clinical, and clinical studies demonstrated their similarity; these studies included RTXM83-AC-01-11, a multicentric double-blind international prospective pivotal study. Long-term data on biosimilars can potentially elucidate their clinical robustness and facilitate their broader adoption.

Methods: In this retrospective observational study, we analyzed a dataset from a Brazilian cohort previously randomized in the RTXM83-AC-01-11 study followed by the assessment of long-term outcomes in an observational extension phase from randomization in the RTXM83-AC-01-11 study to the last recorded evaluation. Patients with diffuse large B cell lymphoma (DLBCL) received either reference rituximab (R) or RTXM83 plus cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) as adjuvant treatment.

Results: The median follow-up period was 77.0 months. Patients with initial DLBCL stages III and IV comprised 50% of the R-CHOP group and 40% of the biosimilar group. Five (18.5%) patients, including two RTXM83-CHOP-treated and three R-CHOP-treated individuals, experienced late adverse events (AEs) of interest. No new safety signs were established. At the final assessment, the progression-free survival (PFS) rates were 93.3% and 50.0% in the RTXM83-CHOP and R-CHOP groups, respectively. Median PFS was not achieved in the RTXM83-CHOP group, which was 40.5 months in the R-CHOP group. The overall survival (OS) rates were 100% and 66.7% in the RTXM83-CHOP and R-CHOP groups, respectively. The median OS was not reached in any group.

Conclusion: This study demonstrated the long-term safety and effectiveness of RTXM83 in treating DLBCL; outcomes comparable to those of the reference product and potentially improved access to treatment have been indicated. However, further research with more diverse patient groups can validate these findings and advocate the broader adoption of biosimilars in cancer care.

Trial Registration: ClinicalTrials.gov Identifier: NCT04928573. June 16, 2021, "retrospectively registered".

References

Salles G, Barrett M, Foa R, Maurer J, OBrien S, Valente N . Rituximab in B-Cell Hematologic Malignancies: A Review of 20 Years of Clinical Experience. Adv Ther. 2017; 34(10):2232-2273. PMC: 5656728. DOI: 10.1007/s12325-017-0612-x. View

Candelaria M, Gonzalez D, Fernandez Gomez F, Paravisini A, Del Campo Garcia A, Perez L . Comparative assessment of pharmacokinetics, and pharmacodynamics between RTXM83™, a rituximab biosimilar, and rituximab in diffuse large B-cell lymphoma patients: a population PK model approach. Cancer Chemother Pharmacol. 2018; 81(3):515-527. DOI: 10.1007/s00280-018-3524-9. View

Gurcan H, Keskin D, Stern J, Nitzberg M, Shekhani H, Ahmed A . A review of the current use of rituximab in autoimmune diseases. Int Immunopharmacol. 2008; 9(1):10-25. DOI: 10.1016/j.intimp.2008.10.004. View

Reff M, Carner K, Chambers K, Chinn P, Leonard J, Raab R . Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood. 1994; 83(2):435-45. View

Recher C, Coiffier B, Haioun C, Molina T, Ferme C, Casasnovas O . Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial. Lancet. 2011; 378(9806):1858-67. DOI: 10.1016/S0140-6736(11)61040-4. View

Susanibar-Adaniya S, Barta S . 2021 Update on Diffuse large B cell lymphoma: A review of current data and potential applications on risk stratification and management. Am J Hematol. 2021; 96(5):617-629. PMC: 8172085. DOI: 10.1002/ajh.26151. View

Gulacsi L, Brodszky V, Baji P, Rencz F, Pentek M . The Rituximab Biosimilar CT-P10 in Rheumatology and Cancer: A Budget Impact Analysis in 28 European Countries. Adv Ther. 2017; 34(5):1128-1144. PMC: 5427122. DOI: 10.1007/s12325-017-0522-y. View

Blackstone E, Joseph P . The economics of biosimilars. Am Health Drug Benefits. 2014; 6(8):469-78. PMC: 4031732. View

Candelaria M, Gonzalez D, Delamain M, Bar D, Beniwal S, Dasappa L . Rituximab biosimilar RTXM83 versus reference rituximab in combination with CHOP as first-line treatment for diffuse large B-cell lymphoma: a randomized, double-blind study. Leuk Lymphoma. 2019; 60(14):3375-3385. DOI: 10.1080/10428194.2019.1633632. View

10.

Bankar A, Korula A, Abraham A, Viswabandya A, George B, Srivastava A . Comparison of the Efficacy of Innovator Rituximab and its Biosimilars in Diffuse Large B Cell Lymphoma Patients: A Retrospective Analysis. Indian J Hematol Blood Transfus. 2020; 36(1):71-77. PMC: 7042466. DOI: 10.1007/s12288-019-01167-w. View

11.

Cuello H, Segatori V, Alberto M, Pesce A, Alonso D, Gabri M . Comparability of Antibody-Mediated Cell Killing Activity Between a Proposed Biosimilar RTXM83 and the Originator Rituximab. BioDrugs. 2016; 30(3):225-31. DOI: 10.1007/s40259-016-0171-8. View

12.

Greenwald M, Tesser J, Sewell K . Biosimilars Have Arrived: Rituximab. Arthritis. 2018; 2018:3762864. PMC: 5885398. DOI: 10.1155/2018/3762864. View

13.

Lee K, Ha J, Jung A, Lee Y, Lee S, Ryu J . The clinical outcomes of rituximab biosimilar CT-P10 (Truxima) with CHOP as first-line treatment for patients with diffuse large B-cell lymphoma: real-world experience. Leuk Lymphoma. 2020; 61(7):1575-1583. DOI: 10.1080/10428194.2020.1742906. View

14.

Sanz I . Indications of rituximab in autoimmune diseases. Drug Discov Today Ther Strateg. 2010; 6(1):13-19. PMC: 2850537. DOI: 10.1016/j.ddstr.2009.10.001. View

15.

Tabernero J, Vyas M, Giuliani R, Arnold D, Cardoso F, Casali P . Biosimilars: a position paper of the European Society for Medical Oncology, with particular reference to oncology prescribers. ESMO Open. 2017; 1(6):e000142. PMC: 5419210. DOI: 10.1136/esmoopen-2016-000142. View

16.

Hedstrom G, Hagberg O, Jerkeman M, Enblad G . The impact of age on survival of diffuse large B-cell lymphoma - a population-based study. Acta Oncol. 2014; 54(6):916-23. DOI: 10.3109/0284186X.2014.978367. View

17.

Jemal A, Bray F, Center M, Ferlay J, Ward E, Forman D . Global cancer statistics. CA Cancer J Clin. 2011; 61(2):69-90. DOI: 10.3322/caac.20107. View

18.

Candelaria M, Duenas-Gonzalez A . Rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in diffuse large B-cell lymphoma. Ther Adv Hematol. 2021; 12:2040620721989579. PMC: 7970687. DOI: 10.1177/2040620721989579. View

19.

Lyman G, Balaban E, Diaz M, Ferris A, Tsao A, Voest E . American Society of Clinical Oncology Statement: Biosimilars in Oncology. J Clin Oncol. 2018; 36(12):1260-1265. DOI: 10.1200/JCO.2017.77.4893. View

20.

Bishton M, Salles G, Golfier C, Knauf W, Bocchia M, Turner D . Real-world clinical effectiveness and safety of CT-P10 in patients with diffuse large B-cell lymphoma: An observational study in Europe. EJHaem. 2023; 4(1):45-54. PMC: 9928637. DOI: 10.1002/jha2.593. View